Trials / Completed
CompletedNCT01713335
Proteasis Evaluation in COPD
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 134 (actual)
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France · Other Government
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.
Conditions
Timeline
- Start date
- 2012-10-18
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2012-10-24
- Last updated
- 2021-08-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01713335. Inclusion in this directory is not an endorsement.